Neal Zung, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4 Elm Pl, Armonk, NY 10504 Phone: 914-450-0723 Fax: 914-273-3820 |
Chung Park, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 23 Lyons Rd, Armonk, NY 10504 Phone: 914-273-6988 Fax: 877-464-4042 |
Dr. Bruce David Kaufman, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 5 Patriots Farm Place, Armonk, NY 10504 Phone: 914-725-8855 Fax: 914-725-8877 |
Dr. Rosanna Christina Perretta, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Patriots Farm Ct, Armonk, NY 10504 Phone: 914-907-9347 |
Dr. Andrew Alexander Nychka, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 10 Nichols Rd, Armonk, NY 10504 Phone: 914-523-0294 Fax: 914-273-0056 |
News Archive
We use both sides of our brain for speech, a finding by researchers at New York University and NYU Langone Medical Center that alters previous conceptions about neurological activity. The results, which appear in the journal Nature, also offer insights into addressing speech-related inhibitions caused by stroke or injury and lay the groundwork for better rehabilitation methods.
In one of the largest pay hitches of its kind in the recent years, the Queensland government has been forced to apologize for shortchanging thousands of doctors and nurses. Due to a recent new system of pay there has been an error in payment with several complaints from the injured parties. With the Easter break round the corner many are frazzled with the error.
The Los Angeles Times reports: "Some of the most vociferous opposition to the proposals before the House and Senate comes from residents of rural states that could benefit most if the present system is revamped.
FDA has approved a porcine insulin zinc suspension product as the first drug for treating diabetic dogs. Prior to the development of this product, the only treatment veterinarians could use on diabetic dogs was human insulin, which is less compatible with a dog's metabolic system.
Ferrer, a privately-held Spanish pharmaceutical company, today announces that the first patient has been recruited into a second phase III trial of Ozenoxacin, formulated as a topical treatment for infectious dermatological conditions in adult and paediatric patients with impetigo. The study is scheduled to complete in Q1, 2015.
› Verified 7 days ago